XML 26 R16.htm IDEA: XBRL DOCUMENT v3.8.0.1
Note 9 - Stock Based Compensation
9 Months Ended
Sep. 30, 2017
Notes to Financial Statements  
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]
(
9
)
Stock Based Compensation
 
The Company recognizes compensation costs for stock option
s awarded to employees based on their grant-date fair value. The value of each stock option is estimated on the date of grant using the Black-Scholes option-pricing model. The weighted-average fair value per share for the stock options granted to employees during the
nine
months ended
September 30, 2017
was
$20.14.
The weighted-average fair value per share for the stock options granted to employees during the
nine
months ended
September 30, 2016
was
$13.82.
 
For the
three
months ended
September 30, 2017
and
2016,
the Company recorded
$1,187
and
$1,012,
respectively, in “Selling, general and administrative expenses” for stock options. For the
nine
months ended
September 30, 2017
and
2016,
the Company recorded
$3,313
and
$2,836,
respectively, in “Selling, general and administrative expenses” for stock options. As of
September 30, 2017,
the total compensation cost related to unvested stock options
not
yet recognized was
$7,224.
The cost will be amortized on a straight-line basis over the remaining weighted-average vesting period of
1.9
years.
 
The following table is a summary of the Company
’s stock options:
 
Options
 
Number of
Shares
   
Weighted
Average
Exercise Price
 
                 
Outstanding at December 31, 2016
   
1,519,338
    $
25.22
 
Granted
   
39,037
     
54.15
 
Exercised
   
(61,249
)    
11.83
 
Outstanding at March 31, 2017
   
1,497,126
     
26.52
 
Granted
   
19,598
     
58.98
 
Exercised
   
(162,431
)    
13.84
 
Outstanding at June 30, 2017
   
1,354,293
     
28.51
 
Exercised
   
(55,950
)    
8.48
 
Outstanding at September 30, 2017
   
1,298,343
     
29.37
 
Exercisable at September 30, 2017
   
449,959
    $
21.09
 
 
The aggregate intrinsic values for all stock options exercised for the
three
and
nine
months ended
September 30, 2017
were
$2,669
and
$12,011,
respectively. The aggregate intrinsic values for all stock options exercised for the
three
and
nine
months ended
September 30, 2016
were
$173
and
$8,195,
respectively. The aggregate intrinsic values for all stock options outstanding and exercisable as of
September 30, 2017
were
$33,350
and
$15,256,
respectively.
 
The following table is a summary of the Company’s unvested stock options, restricted stock and performance shares for which the requisite service period has
not
been rendered but that are expected to vest on the achievement of a performance condition:
 
   
Unvested Stock Options
   
Unvested Restricted Stock
   
Unvested Performance Shares
 
   
Number
of Shares
   
Weighted-
Average
Grant-Date
Fair Value
   
Number of
Shares
   
Weighted-
Average
Grant-Date
Fair Value
   
Number of
Shares
   
Weighted-
Average
Grant-Date
Fair Value
 
                                                 
Unvested at December 31, 2016
   
817,540
    $
12.50
     
260
    $
41.05
     
316,750
    $
30.08
 
Granted
   
39,037
     
21.02
     
-
     
-
     
-
     
-
 
Vested during period
   
(14,975
)    
8.16
     
-
     
-
     
-
     
-
 
Unvested at March 31, 2017
   
841,602
     
12.97
     
260
     
41.05
     
316,750
     
30.08
 
Granted
   
19,598
     
18.37
     
9,496
     
58.98
     
5,750
     
41.36
 
Vested during period
   
(12,816
)    
8.50
     
(260
)    
41.05
     
-
     
-
 
Unvested at June 30, 2017
   
848,384
     
13.17
     
9,496
     
58.98
     
322,500
     
30.28
 
Vested during period
   
-
     
-
     
-
     
-
     
(150,000
)    
17.81
 
Unvested at September 30, 2017
   
848,384
    $
13.17
     
9,496
    $
58.98
     
172,500
    $
41.12
 
 
For the
three
months ended
September 30, 2017
and
2016,
the Company recorded
$280
and
$240,
respectively, in “Selling, general and administrative expenses” for restricted stock awards. For the
nine
months ended
September 30, 2017
and
2016,
the Company recorded
$474
and
$406,
respectively, in “Selling, general and administrative expenses” for restricted stock awards. As of
September 30, 2017,
total compensation cost related to unvested restricted stock
not
yet recognized was
$93.
The cost will be amortized on a straight-line basis over the remaining weighted-average vesting period of
0.1
years.
 
The Company granted equity-settled performance shares (“PS”) to certain executives. PS awards provide the recipient the right to receive a certain number of shares of the Company’s common stock in the future, which depends on the Company’s level of achievement of net revenue and EBITDA growth as compared to the net revenue and EBITDA growth of the members of a specified peer group of companies over a
three
year period. For the
three
months ended
September 30, 2017
and
2016,
the Company recorded
$821
and
$637,
respectively, in “Selling, general and administrative expenses” related to these PS awards. For the
nine
months ended
September 30, 2017
and
2016,
the Company recorded
$2,534
and
$1,947,
respectively, in “Selling, general and administrative expenses” related to these PS awards. As of
September 30, 2017,
total compensation cost related to unvested performance shares
not
yet recognized was
$3,143.
The cost will be amortized on a straight-line basis over the remaining weighted-average vesting period of
1.3
years.